Kaplan-Meier survival analysis showed that patients with highly ZDHHC17- expressing glioma had shorter disease-free survival (DFS) and OS than the low-expression groups; similar results were also obtained for patients with highly expression of MAP2K4 (Figures 3D-3G). Here, MAP2K4 is linked to central nervous system cancer.